Hong-Jie Jhou, Li-Yu Yang, Po-Huang Chen, Cho-Hao Lee
{"title":"Thrombectomy for patients with a large infarct core: a study-level meta-analysis with trial sequential analysis.","authors":"Hong-Jie Jhou, Li-Yu Yang, Po-Huang Chen, Cho-Hao Lee","doi":"10.1177/17562864241285552","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effectiveness and safety of endovascular treatment compared with medical management alone regarding outcomes for patients with a large infarct core remain uncertain.</p><p><strong>Objectives: </strong>To juxtapose the clinical outcomes of thrombectomy versus the best medical care in patients with a large infarct core.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>We conducted searches in PubMed, Cochrane, and Embase for articles published up until November 8, 2023. Randomized trials were selected for inclusion if they encompassed patients with large vessel occlusion and sizable strokes receiving thrombectomy. The primary outcome was functional outcomes at 3 months after pooling data using random-effects modeling. Safety outcomes included mortality at 3 months, symptomatic intracranial hemorrhage (SICH), and decompressive craniectomy. We performed a trial sequential analysis to balance type I and II errors.</p><p><strong>Results: </strong>From 904 citations, we identified six randomized trials, involving a cohort of 1897 patients with a large ischemic region. Of these, 953 individuals underwent endovascular thrombectomy. At 3 months, thrombectomy was significantly correlated with better neurological prognosis, as evidenced by the increased odds of good functional outcomes (odds ratio (OR), 2.90; 95% confidence interval (CI), 2.08-4.05) and favorable functional outcomes (OR, 2.40; 95% CI, 1.86-3.09). Mortality rates did not demonstrably diminish as a consequence of the endovascular management (OR, 0.78; 95% CI, 0.58-1.06). However, the incidence of SICH was greater in the thrombectomy group compared to those with only medical treatment (5.5% vs 3.2%; OR, 1.77; 95% CI, 1.11-2.83). The application of trial sequential analysis yielded definitive evidence regarding favorable function outcomes and a shift in the distribution of modified Rankin scale scores at 3 months; however, others remained inconclusive.</p><p><strong>Conclusion: </strong>The results from most of the included trials display consistency. Meta-analysis of these six randomized trials offers high-quality evidence that thrombectomy significantly mitigates disability in patients with a large infarction, while also increasing the risk of SICH.</p><p><strong>Trial registration: </strong>PROSPERO, CRD42023480359.</p>","PeriodicalId":22980,"journal":{"name":"Therapeutic Advances in Neurological Disorders","volume":"17 ","pages":"17562864241285552"},"PeriodicalIF":4.7000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462614/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Neurological Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864241285552","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The effectiveness and safety of endovascular treatment compared with medical management alone regarding outcomes for patients with a large infarct core remain uncertain.
Objectives: To juxtapose the clinical outcomes of thrombectomy versus the best medical care in patients with a large infarct core.
Design: Systematic review and meta-analysis.
Data sources and methods: We conducted searches in PubMed, Cochrane, and Embase for articles published up until November 8, 2023. Randomized trials were selected for inclusion if they encompassed patients with large vessel occlusion and sizable strokes receiving thrombectomy. The primary outcome was functional outcomes at 3 months after pooling data using random-effects modeling. Safety outcomes included mortality at 3 months, symptomatic intracranial hemorrhage (SICH), and decompressive craniectomy. We performed a trial sequential analysis to balance type I and II errors.
Results: From 904 citations, we identified six randomized trials, involving a cohort of 1897 patients with a large ischemic region. Of these, 953 individuals underwent endovascular thrombectomy. At 3 months, thrombectomy was significantly correlated with better neurological prognosis, as evidenced by the increased odds of good functional outcomes (odds ratio (OR), 2.90; 95% confidence interval (CI), 2.08-4.05) and favorable functional outcomes (OR, 2.40; 95% CI, 1.86-3.09). Mortality rates did not demonstrably diminish as a consequence of the endovascular management (OR, 0.78; 95% CI, 0.58-1.06). However, the incidence of SICH was greater in the thrombectomy group compared to those with only medical treatment (5.5% vs 3.2%; OR, 1.77; 95% CI, 1.11-2.83). The application of trial sequential analysis yielded definitive evidence regarding favorable function outcomes and a shift in the distribution of modified Rankin scale scores at 3 months; however, others remained inconclusive.
Conclusion: The results from most of the included trials display consistency. Meta-analysis of these six randomized trials offers high-quality evidence that thrombectomy significantly mitigates disability in patients with a large infarction, while also increasing the risk of SICH.
背景:与单纯药物治疗相比,血管内治疗对大面积心梗患者的疗效和安全性仍不确定:与单纯药物治疗相比,血管内治疗对大面积心梗患者的疗效和安全性仍不确定:将血栓切除术的临床疗效与大面积心梗患者的最佳治疗方法进行对比:设计:系统回顾和荟萃分析:我们在PubMed、Cochrane和Embase中检索了截至2023年11月8日发表的文章。如果随机试验涉及接受血栓切除术的大血管闭塞和大面积脑卒中患者,则将这些试验纳入其中。使用随机效应模型汇总数据后,主要结果是3个月后的功能性结果。安全性结果包括 3 个月的死亡率、症状性颅内出血(SICH)和减压开颅手术。我们进行了试验序列分析,以平衡I型和II型误差:我们从904条引文中确定了六项随机试验,涉及1897名大面积缺血患者。其中,953 人接受了血管内血栓切除术。3个月后,血栓切除术与更好的神经预后显著相关,良好功能预后的几率增加(几率比(OR),2.90;95% 置信区间(CI),2.08-4.05)和有利的功能预后(OR,2.40;95% CI,1.86-3.09)证明了这一点。死亡率并未因血管内治疗而明显降低(OR,0.78;95% CI,0.58-1.06)。不过,血栓切除术组的 SICH 发生率高于仅接受药物治疗的一组(5.5% vs 3.2%;OR,1.77;95% CI,1.11-2.83)。应用试验顺序分析法得出了关于3个月后良好功能结果和改良Rankin量表评分分布变化的确凿证据,但其他试验仍无定论:结论:大多数纳入试验的结果具有一致性。对这六项随机试验进行的 Meta 分析提供了高质量的证据,证明血栓切除术能显著减轻大面积心梗患者的残疾程度,同时也增加了 SICH 的风险:试验注册:prospero,CRD42023480359。
期刊介绍:
Therapeutic Advances in Neurological Disorders is a peer-reviewed, open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of neurology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in neurology, providing a forum in print and online for publishing the highest quality articles in this area.